BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 28737478)

  • 1. Family matters: How MYC family oncogenes impact small cell lung cancer.
    Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
    Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
    Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
    Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
    Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
    Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
    Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
    Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
    Sos ML; Dietlein F; Peifer M; Schöttle J; Balke-Want H; Müller C; Koker M; Richters A; Heynck S; Malchers F; Heuckmann JM; Seidel D; Eyers PA; Ullrich RT; Antonchick AP; Vintonyak VV; Schneider PM; Ninomiya T; Waldmann H; Büttner R; Rauh D; Heukamp LC; Thomas RK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):17034-9. PubMed ID: 23035247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
    Ciampricotti M; Karakousi T; Richards AL; Quintanal-Villalonga À; Karatza A; Caeser R; Costa EA; Allaj V; Manoj P; Spainhower KB; Kombak FE; Sanchez-Rivera FJ; Jaspers JE; Zavitsanou AM; Maddalo D; Ventura A; Rideout WM; Akama-Garren EH; Jacks T; Donoghue MTA; Sen T; Oliver TG; Poirier JT; Papagiannakopoulos T; Rudin CM
    Cancer Discov; 2021 Dec; 11(12):3214-3229. PubMed ID: 34344693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
    Tokgun O; Tokgun PE; Inci K; Akca H
    Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
    Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
    Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
    Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer.
    Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H
    Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells.
    Munksgaard Thorén M; Vaapil M; Staaf J; Planck M; Johansson ME; Mohlin S; Påhlman S
    Oncotarget; 2017 Jul; 8(30):48983-48995. PubMed ID: 28430666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
    Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
    J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the activation of the myc family oncogene and of its stability over time in xenografted human lung carcinomas.
    Gazzeri S; Brambilla E; Chauvin C; Jacrot M; Benabid AL; Brambilla C
    Cancer Res; 1990 Mar; 50(5):1566-70. PubMed ID: 2154327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
    Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.